NorthWest Biotherapeutics Inc (NWBO)

[longusa]

Price Elasticity of Label

Try this on: in thinking about the price flexibility that NW will have, an interesting possibility could be that NW works out a broad label approval with regulators in return for low prices.

This would be enabled by the applicability of DCVax to all solid tumor cancers, and the very mild side effects. The deal could be for approval in all solid tumor cancers subject to post-approval confirmatory trials in each current classification subtype, in exchange for aggressive pricing, say $25k for first dose (so that NW is never in a negative financial condition for a patient) and $5k per dose thereafter.

This could make DCVax SoC for all solid tumor cancers much more rapidly than would otherwise be the case.

Food for thought.